REVIEW Nebivolol is a chiral, selective, third-generation beta1-receptor antagonist used in the treatment of hypertension and chronic heart failure. It blocks activation of adrenergic receptors by epinephrine, reversing its effects and lowering heart rate and blood pressure. It has additional nitric oxide-mediated vasodilating and antioxidant properties, along with a favorable metabolic profile.
Noe, Christian R.; Jasic, Muhamed; Kollmann, Hermann; Lachmann, Bodo Process for preparation of Nebivolol using 6-fluoro-3,4-dihydrobenzopyran-2-carboxaldehyde cyanohydrins. PCT Int. Appl. (2007), WO 2007009143 A2 20070125.
Khamar, Bakulesh Mafatlal; Thakor, Indrajit; Patel, Mahesh; Jadav, Kalpesh; Parikh, Ankur; Joshi, Atul Chhotalal; Ponnaiah, Ravi; Modi, Indravadan Ambalal An improved process for the preparation of nebivolol hydrochloride Eur. Pat. Appl. (2010), EP 2163551 A1 20100317.
Maragni, Paolo; Michieletto, Ivan; Volpicelli, Raffaella; Soriato, Giorgio; Foletto, Johnny; Cotarca, Livius; Verzini, Massimo Process for preparing nebivolol PCT Int. Appl. (2010), WO 2010049455 A1 20100506.
Gielen W, Cleophas TJ, Agrawal R: Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther. 2006 Aug;44(8):344-57.
For research use only. Not for diagnostic or therapeutic use. Not for human use. AK Scientific, Inc. does not sell to individuals. If you are a first-time customer, please email for review at least two official business documents issued by your local jurisdiction, state/province, or country.